These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy. Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933 [TBL] [Abstract][Full Text] [Related]
25. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor. Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905 [No Abstract] [Full Text] [Related]
26. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis. Ramsey BW; Welsh MJ Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323 [No Abstract] [Full Text] [Related]
27. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR. Taylor-Cousar JL; Jain M; Barto TL; Haddad T; Atkinson J; Tian S; Tang R; Marigowda G; Waltz D; Pilewski J; J Cyst Fibros; 2018 Mar; 17(2):228-235. PubMed ID: 29126871 [TBL] [Abstract][Full Text] [Related]
28. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results. Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946 [TBL] [Abstract][Full Text] [Related]
29. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis. Mayer-Hamblett N; Boyle M; VanDevanter D Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594 [TBL] [Abstract][Full Text] [Related]
30. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel. Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400 [TBL] [Abstract][Full Text] [Related]
31. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation. Bulloch MN; Hanna C; Giovane R Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346 [TBL] [Abstract][Full Text] [Related]
32. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Connett GJ Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974 [TBL] [Abstract][Full Text] [Related]
33. Metabolomic responses to lumacaftor/ivacaftor in cystic fibrosis. Kopp BT; McCulloch S; Shrestha CL; Zhang S; Sarzynski L; Woodley FW; Hayes D Pediatr Pulmonol; 2018 May; 53(5):583-591. PubMed ID: 29461009 [TBL] [Abstract][Full Text] [Related]
34. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor. Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355 [TBL] [Abstract][Full Text] [Related]
35. The bidirectional relationship between CFTR and lipids. Cottrill KA; Farinha CM; McCarty NA Commun Biol; 2020 Apr; 3(1):179. PubMed ID: 32313074 [TBL] [Abstract][Full Text] [Related]
36. Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators. George A; Smith B; Sawicki GS; Goetz DM Pediatr Pulmonol; 2020 Nov; 55(11):2983-2989. PubMed ID: 32589808 [TBL] [Abstract][Full Text] [Related]
37. Update in Cystic Fibrosis 2014. Ong T; Ramsey BW Am J Respir Crit Care Med; 2015 Sep; 192(6):669-75. PubMed ID: 26371812 [No Abstract] [Full Text] [Related]
38. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713 [TBL] [Abstract][Full Text] [Related]
39. Impact of CFTR-modulating drugs on GH-IGF-1 axis impairment in adult patients with cystic fibrosis. Pascucci C; De Biase RV; Savi D; Quattrucci S; Gnessi L; Lubrano C; Lenzi A J Endocrinol Invest; 2019 Nov; 42(11):1361-1363. PubMed ID: 31006073 [TBL] [Abstract][Full Text] [Related]
40. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction. Brewington JJ; McPhail GL; Clancy JP Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]